Emulate
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology. By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro models that empower researchers to explore the biological mechanisms of health and disease. These microphysiological systems (MPS), commonly known as Organ-Chips, are setting a new standard for how we study biology and develop drugs, therapies, and cures for those who need them most. Leveraging human biology + technology to ignite a new era in human health.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
A History of Innovation
From the beginning, the goal was always to build a more predictive model of human physiology.
The pioneering work on Organ-Chips was begun by our founding team at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Following the landmark paper in Science, “Reconstituting Organ-Level Lung Functions on a Chip,” Emulate was founded to share the success of these efforts with the broader life sciences community. Since our inception, we have been focused on delivering exceptional science across multiple organs and applications.
In 2019, Emulate researchers published a pivotal paper in Science Translational Medicine demonstrating how the mechanisms of drug-induced liver injury can be dissected using the Emulate Liver-Chip. Today, Emulate counts 18 of the top 20 pharmaceutical companies as customers, including leading academic and government entities around the globe. And we’re just getting started.